Postmarketing Surveillance Study of Atrovent® in Chronic Obstructive Airways Disease

Postmarketing Surveillance Study (as Per §67(6)AMG[German Drug Law]) of Atrovent® Unit Dose Vial 500 µg in Chronic Obstructive Airways Disease

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02236715

Enrollment

1039

Registered

2014-09-11

Start date

1999-09-30

Completion date

Unknown

Last updated

2014-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Brief summary

Study to obtain further information on the tolerability and efficacy of Atrovent® unit dose vial 500 µg in the treatment of Chronic Obstructive Airways Disease under conditions of daily practice

Interventions

DRUGAtrovent®

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

30 Years to No maximum

Healthy volunteers

Inclusion criteria

* Primarily patients of both gender, older than 30 years, who suffer from chronic obstructive airways disease * Only patients who had not been treated with Atrovent® within the last year were to be considered for inclusion

Exclusion criteria

* Contraindication listed in the instructions for use/summary of product characteristics for Atrovent® unit dose vial 500 µg

Design outcomes

Primary

Measure	Time frame
Change in total severity of the clinical picture rated on a 4-point scale	after 4 weeks

Secondary

Measure	Time frame
Assessment of efficacy by investigator on a 4-point scale	after 4 weeks
Assessment of efficacy by patient on a 4-point scale	after 4 weeks
Assessment of tolerability by investigator on a 4-point scale	after 4 weeks
Assessment of tolerability by patient on a 4-point scale	after 4 weeks
Number of patients with adverse drug reactions	up to 4 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026